Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Sudarshan Pharma Industries's 3-Year RORE % for the quarter that ended in Jun. 2026 was 63.37%.
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Sudarshan Pharma Industries 3-Year RORE % Related Terms
Sudarshan Pharma Industries 3-Year RORE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Chemicals subindustry, Sudarshan Pharma Industries's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sudarshan Pharma Industries 3-Year RORE % vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Sudarshan Pharma Industries's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Sudarshan Pharma Industries's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Jun. 2026 and 3-year before.
Sudarshan Pharma Industries (BOM:543828) has a 3-Year RORE % of 63.37 as of Jun. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Sudarshan Pharma Industries and its competitors. According to the industry distribution chart, Sudarshan Pharma Industries ranks #247 out of 1526 companies in the Chemicals industry, placing it in the top 16.2%.
Is Sudarshan Pharma Industries' 3-Year RORE % too high?
Sudarshan Pharma Industries' current 3-Year RORE % is 63.37. The Chemicals industry median 3-Year RORE % is 8.91. Sudarshan Pharma Industries' value of 63.37 is 611.2% above this industry median. Based on the distribution chart, Sudarshan Pharma Industries ranks #247 out of 1526 companies in the Chemicals industry, which is in the top quartile — a strong position relative to peers. Overall, Sudarshan Pharma Industries has a GF Score™ of 72/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sudarshan Pharma Industries' 3-Year RORE % compare to DOW?
According to the Chemicals industry distribution chart, Sudarshan Pharma Industries ranks #247 out of 1526 companies for 3-Year RORE %. This places Sudarshan Pharma Industries in the top 16% of its industry — outperforming the majority of peers. The industry median 3-Year RORE % is 8.91. Sudarshan Pharma Industries' value of 63.37 is 611.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Chemicals company?
The median 3-Year RORE % among Chemicals companies is 8.91, based on 1,526 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sudarshan Pharma Industries's current 3-Year RORE % of 63.37 is 611.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Sudarshan Pharma Industries and its competitors. For the Chemicals industry, the median 3-Year RORE % is 8.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sudarshan Pharma Industries's current 3-Year RORE % is 63.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sudarshan Pharma Industries stock overvalued right now?
Based on GuruFocus' analysis, Sudarshan Pharma Industries (BOM:543828) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹24.98, compared to a current price of ₹38.97 — trading 56% above its estimated fair value. The current 3-Year RORE % is 63.37 and 611.2% above the Chemicals industry median of 8.91. Sudarshan Pharma Industries' overall GF Score™ is 72/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Sudarshan Pharma Industries (BOM:543828), the current 3-Year RORE % is 63.37 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sudarshan Pharma Industries (BOM:543828) Overvalued in 2026?
Based on GuruFocus' analysis, Sudarshan Pharma Industries stock appears to be overvalued.
The current stock price of ₹38.97 is trading 56% above its estimated GF Value™ of ₹24.98.
GuruFocus considers Sudarshan Pharma Industries to be Significantly Overvalued.
Key valuation signals for BOM:543828:
3-Year RORE %: 63.37
GF Value™: ₹24.98 vs. price of ₹38.97 (56% above fair value)
Industry Position: 611.2% above the Chemicals median (#247 of 1526)
No single metric tells the full story. See the BOM:543828 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sudarshan Pharma Industries Ltd operates in the pharmaceutical and chemical industries, focusing on specialty chemicals and intermediates used in pharmaceuticals, paints, food products, and adhesives. The Company has a presence domestically and internationally, participating regularly in trade fairs and exhibitions. The Company exports mainly to South East Asia, the Middle East, and North Africa. The Company also supplies generic pharmaceutical formulation as 'Make to order' for bulk supply to hospitals and related healthcare organisations. The company has one reportable segment of Specialty Chemicals.
72GF Score
Get the complete analysis for BOM:543828
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543828 has been successfully added to your 
